Triple-negative breast cancer: open trials in Mexico

• NCT06393374

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Grupo Médico ASSET SC (Site 0705), Benito Juárez · CENEIT Oncologicos (Site 0706), Mexico City · Health Pharma Professional Research S.A. de C.V: (Site 0709), Mexico City · COI Centro Oncologico Internacional S.A.P.I. de C.V. (Site 0712), Mexico City · Oncare - Unidad Valle (Site 0713), San Pedro Garza García · CENTRO MEDICO ZAMBRANO HELLION (Site 0711), San Pedro Garza García

  Registry updated 2026-11-05

• NCT07173751

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  Trial Treatment · Phase 3 · BioNTech SE

  Centro de Investigacion Oncologica Galeias, Aguascalientes · Preparaciones Oncológicas S.C., León · Centro de Atención Oncológica Viva, Mexico City · Onco Pall Advance Care Oncology Center Sa de CV, Monterrey · Oncologico Potosino, San Luis Potosí City · Investigacion Biomedica para el Desarrollo de Nuevos Farmacos SA de CV, Zapopan

  Registry updated 2026-10-30

• NCT06841354

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Centro de Investigación Oncológica Galerías SC (Site 2511), Aguascalientes · Grupo Médico ASSET SC (Site 2507), Benito Juárez · Unidad de Mastologia Avanzada de Chihuahua S.A de C.V (Site 2510), Chihuahua City · CIO - Centro de Inmuno-Oncología de Occidente (Site 2504), Guadalajara · COI Centro Oncologico Internacional S.A.P.I. de C.V. (Site 2514), Mexico City · Centro Oncologico de Alta Especialidad, S.C. (Site 2509), Mexico City · Higiea Oncologia (Site 2505), Mexico City · Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" (Site 2501), Monterrey · Filios Alta Medicina (Site 2506), Monterrey · Centro de Investigacion Clinica de Oaxaca (Site 2503), Oaxaca City · Centro Potosino de Investigación Médica (Site 2512), San Luis Potosí City · Oncare - Unidad Valle (Site 2502), San Pedro Garza García

  Registry updated 2026-10-13

• NCT06103864

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  Trial Treatment · Phase 3 · AstraZeneca

  CD Mexico · Guadalajara · México · Mexico City · Tuxtla Gutiérrez

  Registry updated 2026-09-25

• NCT06926868

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  Trial Treatment · Phase 2/3 · Bristol-Myers Squibb

  Scientia Investigacion Clinica S.C., Chihuahua City · Guadalajara · Mérida · Mexico City · CENEIT Oncologicos, Mexico City · Monterrey · Monterrey · Monterrey · Oaxaca City · Tijuana

  Registry updated 2026-08-10

• NCT05929768

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  Trial Treatment · Phase 3 · SWOG Cancer Research Network

  Instituto Nacional De Cancerologia de Mexico, Mexico City

  Registry updated 2025-11-05

All Triple-negative breast cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error